tiprankstipranks
Trending News
More News >
333D Limited (AU:T3D)
:T3D
Australian Market

333D Limited (T3D) AI Stock Analysis

Compare
1 Followers

Top Page

AU

333D Limited

(Sydney:T3D)

Rating:28Underperform
Price Target:
The most significant factor impacting 333D Limited's stock score is its poor financial performance, characterized by negative profitability, a weak balance sheet, and inadequate cash flow. The lack of technical analysis data and negative valuation metrics further highlight the company's financial distress. Without earnings call or corporate events data to provide additional context or potential positive outlooks, the overall score remains low.

333D Limited (T3D) vs. iShares MSCI Australia ETF (EWA)

333D Limited Business Overview & Revenue Model

Company Description333D Limited (T3D) is an Australian-based company specializing in 3D printing technologies and services. The company operates within the technology and manufacturing sectors, providing innovative 3D printing solutions to a diverse clientele, including industries such as education, architecture, and consumer products. 333D Limited focuses on delivering high-quality 3D printed products and services, leveraging advanced technology to meet the demands of its customers.
How the Company Makes Money333D Limited generates revenue primarily through the sale of 3D printed products and services. The company offers customized 3D printing solutions to various sectors, enabling clients to create prototypes, models, and finished goods. Additionally, 333D Limited may engage in partnerships with other businesses to expand its market reach and enhance its product offerings. The company could also explore opportunities in licensing its technology or collaborating on research and development initiatives to further drive its revenue streams. However, specific details about significant partnerships or additional revenue factors are currently unavailable.

333D Limited Financial Statement Overview

Summary
333D Limited is facing substantial financial challenges. Despite some revenue growth, the company struggles with profitability and has a weak balance sheet. The high level of liabilities and negative equity highlight potential solvency issues. Cash flow improvements are insufficient to mitigate operational losses, indicating a need for strategic changes to achieve financial stability.
Income Statement
15
Very Negative
The company has seen significant volatility in its revenue over the years with recent improvements. However, profitability remains a concern as indicated by persistent negative net income and EBIT margins. Gross profit has improved recently, but overall profitability metrics are poor, reflecting ongoing financial struggles.
Balance Sheet
10
Very Negative
The company exhibits a weak balance sheet with negative equity and high liabilities relative to assets. The debt-to-equity ratio is concerning, although recent reductions in debt are positive. The equity ratio is negative, indicating a financially distressed position with potential insolvency risks.
Cash Flow
20
Very Negative
Cash flow from operations has shown some improvement, but remains negative, indicating ongoing operational challenges. The free cash flow is negative, reflecting inadequate cash generation to cover investments and obligations. The company shows poor cash flow sustainability with high volatility in past years.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue630.58K190.31K23.95K63.68K114.97K186.15K
Gross Profit298.48K181.29K-146.37K-209.88K-24.78K-281.53K
EBITDA1.14K-600.60K-842.81K0.00-215.92K-845.40K
Net Income-418.15K-506.61K-724.97K-1.24M-338.79K-598.09K
Balance Sheet
Total Assets150.77K24.68K89.29K441.52K132.40K34.74K
Cash, Cash Equivalents and Short-Term Investments52.34K4.58K65.05K415.73K99.21K9.16K
Total Debt0.000.000.000.00300.00K1.30M
Total Liabilities486.73K553.85K505.88K365.68K678.88K2.40M
Stockholders Equity-335.96K-529.17K-416.60K75.84K-546.47K-2.36M
Cash Flow
Free Cash Flow-290.02K-60.46K-350.69K-195.78K90.04K-22.09K
Operating Cash Flow-290.02K-60.46K-350.69K-195.78K90.04K-22.09K
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow340.43K0.000.00512.30K0.000.00

333D Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (50)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCAT
68
Neutral
$1.61B-10.89%17.79%11.08%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
AURHT
61
Neutral
AU$18.38M140.00-3.11%89.13%69.57%
50
Neutral
AU$1.52B1.82-28.25%3.28%16.21%-7.40%
AUAD1
46
Neutral
AU$7.32M-245.01%-17.50%66.33%
AUBRN
42
Neutral
$390.79M-133.28%72.47%20.08%
AUBRN
42
Neutral
$390.79M-133.28%72.47%20.08%
AUT3D
28
Underperform
AU$1.06M
1110.63%30.61%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:T3D
333D Limited
0.01
0.00
0.00%
AU:CAT
Catapult Group International
5.82
4.04
226.97%
AU:BRN
BrainChip Holdings
0.20
>-0.01
-4.88%
AU:BRN
BrainChip Holdings
0.20
>-0.01
-4.88%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:AD1
AD1 Holdings Ltd
0.05
0.00
0.00%

333D Limited Corporate Events

333D Limited Reports Revenue Growth and New Healthcare Contracts
Apr 23, 2025

333D Limited reported an increase in cash receipts from customers, totaling $268,339 for the quarter ending March 2025, marking a 1.92% rise from the previous quarter. The company secured two new contracts with healthcare providers, generating over $690,000 in revenue from July to March 2025, reflecting its growing presence in digital asset management and 3D printing services. The net operating cash received was $23,012, and the company incurred expenditures of approximately $245,643, with no material events occurring after the quarter.

333D Limited Appoints John Conidi as CEO to Drive Digital Asset Strategy
Mar 6, 2025

333D Limited has appointed Mr. John Conidi as the new CEO and Managing Director, effective March 1, 2025. Mr. Conidi, a substantial shareholder and current director, has been pivotal in advancing the company’s digital asset management strategy, which has led to significant revenue growth in the medical digital asset sector. The company’s focus on R&D to automate processes aligns with the anticipated increase in radiology presentations due to government commitments to Medicare, potentially enhancing operational efficiency and cost-effectiveness for partners.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025